5 Key Takeaways from the PATHFINDER 2 Study

Nima Nabavizadeh, MD discusses 5 key takeaways from the PATHFINDER 2 study, a prospective, multi-center interventional study of GRAIL’s multi-cancer early detection (MCED) test. These findings were initially presented at the ESMO Congress 2025. Learn more about MCED: http://galleri.com http://grail.com Galleri should be used in addition to healthcare provider recommended screening tests. The Galleri test does not detect a signal for all cancers, and not all cancers can be detected in the blood. False-positive and false-negative results do occur. Galleri is a screening test and does not diagnose cancer. Diagnostic testing is needed to confirm cancer. Rx only. See Important Safety Information: https://www.galleri.com/safety-information